Virpax Pharmaceuticals https://validator.w3.org/feed/docs/rss2.html Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study Virpax’s Matthew Barnes to Present at Outsourcing in Clinical Trials Conference Virpax Looking to Use MET to Develop Intranasal COVID Vaccine Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants Virpax Regains Compliance with Nasdaq Minimum Bid Price Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 Governance JATINDER (JAY) DHALIWAL Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™ Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™ Team Virpax® Pharmaceuticals to Present at 2024 BIO International Convention Global Sublicensing Plan Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Epoladerm for the Management of Osteoarthritis of the Knee Virpax Pharmaceuticals Announces Reverse Stock Split Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding Virpax Announces Pricing of $2.25 Million Public Offering Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™ Virpax’s MMS019 Inhibits SARS-COV-2 in Ex-Vivo Airway Model Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses Investors Products Behind the Science Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. Virpax Pharmaceuticals Reports 2023 Year-End Results Virpax Pharmaceuticals Updates on Litigation Virpax’s MMS019 Reduced Nasal and Brain Viral Load in Animal Study Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™ Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™ Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™ Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis Virpax Pursues OTC Medical Device Pathway for AnQlar™ Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement Contact Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™ Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019 About Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm(TM) Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research Home